Literature DB >> 31042799

Viability of Mouse Retinal Explant Cultures Assessed by Preservation of Functionality and Morphology.

Virpi Alarautalahti1, Symantas Ragauskas2, Jenni J Hakkarainen2, Hannele Uusitalo-Järvinen1,3, Hannu Uusitalo1,3, Jari Hyttinen1, Giedrius Kalesnykas2, Soile Nymark1.   

Abstract

Purpose: Retinal explant cultures provide simplified systems where the functions of the retina and the effects of ocular therapies can be studied in an isolated environment. The purpose of this study was to provide insight into long-term preservation of retinal tissue in culture conditions, enable a deeper understanding of the interdependence of retinal morphology and function, and ensure the reliability of the explant technique for prolonged experiments.
Methods: Retinal explants from adult mice were cultured as organotypic culture at the air-medium interface for 14 days in vitro (DIV). Retinal functionality was assessed by multielectrode array technique and morphology by immunohistochemical methods at several time points during culture.
Results: Retinal explants retained viability for 14 DIV, although with diminishing neuronal activity, progressing neuronal loss, and increasing reactive gliosis. We recorded spontaneous retinal ganglion cell (RGC) activity up to 14 DIV with temporally changing distribution of RGC firing rates. Light responsiveness was measurable from RGCs for 7 DIV and from photoreceptors for 2 DIV. Apoptotic cells were detected beginning at 3 DIV with their density peaking at 7 DIV. The number of RGCs gradually decreased by 70% during 14 DIV. The change was accompanied by the loss of RGC functionality, resulting in 84% loss of electrically active RGCs. Conclusions: Retinal explants provide a valuable tool for studies of retinal functions and development of ocular therapies. However, critical for long-term use, retinal functionality was lost before structural loss, emphasizing a need for both functional and morphologic readouts to determine the overall state of the cultured retina.

Entities:  

Mesh:

Year:  2019        PMID: 31042799     DOI: 10.1167/iovs.18-25156

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  5 in total

1.  Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury.

Authors:  Abdelrahman Y Fouda; Wael Eldahshan; Zhimin Xu; Tahira Lemtalsi; Esraa Shosha; Syed Ah Zaidi; Ammar A Abdelrahman; Paul Ning-Man Cheng; S Priya Narayanan; R William Caldwell; Ruth B Caldwell
Journal:  Exp Neurol       Date:  2021-11-12       Impact factor: 5.620

2.  Chronic Activation of Gp1 mGluRs Leads to Distinct Refinement of Neural Network Activity through Non-Canonical p53 and Akt Signaling.

Authors:  Dai-Chi Liu; Stephanie Soriano; Yeeun Yook; Simon Lizarazo; Daphne E Eagleman; Nien-Pei Tsai
Journal:  eNeuro       Date:  2020-03-27

3.  Evaluation of neuroprotective and immunomodulatory properties of mesenchymal stem cells in an ex vivo retinal explant model.

Authors:  Élodie Reboussin; Juliette Buffault; Françoise Brignole-Baudouin; Annabelle Réaux-Le Goazigo; Luisa Riancho; Céline Olmiere; José-Alain Sahel; Stéphane Mélik Parsadaniantz; Christophe Baudouin
Journal:  J Neuroinflammation       Date:  2022-03-02       Impact factor: 8.322

4.  Role of the Internal Limiting Membrane in Structural Engraftment and Topographic Spacing of Transplanted Human Stem Cell-Derived Retinal Ganglion Cells.

Authors:  Kevin Y Zhang; Caitlyn Tuffy; Joseph L Mertz; Sarah Quillen; Laurence Wechsler; Harry A Quigley; Donald J Zack; Thomas V Johnson
Journal:  Stem Cell Reports       Date:  2020-12-30       Impact factor: 7.765

5.  Retinal Phenotyping of Ferrochelatase Mutant Mice Reveals Protoporphyrin Accumulation and Reduced Neovascular Response.

Authors:  S P B Sardar Pasha; Trupti Shetty; Nathan A Lambert-Cheatham; Kamakshi Sishtla; Deepa Mathew; Anbukkarasi Muniyandi; Neeta Patwari; Ashay D Bhatwadekar; Timothy W Corson
Journal:  Invest Ophthalmol Vis Sci       Date:  2021-02-01       Impact factor: 4.925

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.